MarketPulse
C

$CORT

73 articles found
2 positive
71 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Corcept Investors Face April Deadline in Securities Fraud Class Action Over Drug Trial Data

Rosen Law Firm files securities fraud class action against Corcept Therapeutics, alleging misrepresentation of relacorilant drug trial data. Lead plaintiff deadline: April 21, 2026.
CORTMNDYHCXYHTGCsecurities class actionrelacorilant
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Class Action Against Concorde International Group

Rosen Law Firm filed class action against Concorde International Group alleging false statements and fraudulent disclosures. Investors have until May 20, 2026 to serve as lead plaintiff.
CORTENPHCIGLsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Corcept Therapeutics Faces Securities Lawsuit Over Alleged Drug Trial Misrepresentations

Rosen Law Firm pursues class action against $CORT for allegedly misrepresenting relacorilant clinical trial data and FDA communications. Lead plaintiff deadline: April 21, 2026.
CORTENPHCIGLsecurities class actionrelacorilant
The Motley FoolThe Motley Fool··Eric Volkman

Corcept Therapeutics Surges 9% on FDA Approval of Cancer Drug Lifyorli

Corcept Therapeutics stock surged 9% following FDA approval of cancer drug Lifyorli. An analyst upgraded the stock to hold amid concerns about existing Korlym franchise performance.
CORTFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Corcept Faces Securities Lawsuit After FDA Rejection, $2.5B Market Wipeout

Hagens Berman sues $CORT over alleged concealment of FDA warnings on relacorilant. Stock crashed 50% following Complete Response Letter, erasing $2.5B in market value.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Faces Class Action Over Relacorilant Trial Claims and FDA Disclosure Gaps

Lawsuit filed against Corcept Therapeutics alleging false statements about relacorilant drug trials and FDA communications, covering October 2024-December 2025 investor purchases.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

CORT Stock Plunges 50% on FDA Rejection; Securities Fraud Lawsuit Filed

Corcept Therapeutics shares crashed 50% after FDA rejected relacorilant application. Class action lawsuit alleges company concealed prior FDA warnings about clinical development concerns.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

CORT Stock Tanks 50% on Failed FDA Review; Class Action Lawsuit Deadline Looms

Corcept Therapeutics faces class action lawsuit after FDA rejected lead drug relacorilant in December. Stock fell 50.4%; investors with $100K+ losses have until April 2026 to file suit.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Corcept Stock Crashes 50% After FDA Rejection and Patent Loss Spark Securities Lawsuit

Hagens Berman files securities class action against $CORT after FDA rejection of lead drug and federal court patent loss, alleging concealment of clinical data warnings.
CORTsecurities class actionFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Corcept Therapeutics Faces Securities Fraud Suit Over Undisclosed FDA Setback

Class action lawsuit filed against Corcept Therapeutics alleging securities fraud tied to FDA rejection of relacorilant, triggering 50% stock plunge.
CORTQURETCOMsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Faces Class Action Over Relacorilant Claims as Investors Allege Misleading Trial Data

Class action lawsuit filed against $COPT alleging executives misrepresented relacorilant clinical trial strength and FDA approval prospects, harming investors.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Corcept Faces Securities Lawsuit Over Relacorilant Clinical Data Misrepresentation

Rosen Law Firm notifies Corcept investors about securities lawsuit alleging misrepresentation of relacorilant clinical data and concealment of FDA concerns during October 2024-December 2025.
CORTsecurities class actionrelacorilant
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Securities Class Action Filed Against Concorde International Group Over Alleged Fraud Scheme

Rosen Law Firm filed securities class action against Concorde International Group ($CIGL) alleging fraudulent promotion schemes and insider share dumping. Affected investors must act before critical deadlines.
CORTBYNDCIGLsecurities class actionmisleading statements
BenzingaBenzinga··Piero Cingari

Oil Surges to $110 as Stagflation Fears Grip Markets; Stocks Hit 4-Month Lows

U.S. stocks fell to four-month lows as Brent crude hit $110 and rate-hike odds climbed, spurring stagflation concerns and precious metals selloff.
CORTDELLSPYQQQNVDA+6market volatilityprecious metals
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Corcept Therapeutics Faces Securities Fraud Class Action Over Relacorilant FDA Claims

Class action lawsuit filed against $CORP alleging false statements about relacorilant clinical trial strength and FDA approval prospects. Investors from Oct 2024-Dec 2025 urged to participate.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Corcept Stock Tanks 50% After FDA Rejection, Class Action Lawsuit Filed

Corcept Therapeutics faces class action lawsuit for allegedly misrepresenting FDA trial data; stock collapsed 50% after regulatory rejection of relacorilant drug.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Corcept Stock Crashes 50% on FDA Rejection; Class Action Deadline Looms

FDA rejects Corcept's lead drug candidate, triggering 50% stock plunge and securities class action lawsuit. Lead plaintiff deadline set for April 21, 2026.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Corcept Therapeutics Plummets 50% After FDA Rejects Lead Drug; Class Action Lawsuit Filed

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant. Stock crashed 50% following misleading investor claims about approval prospects.
CORTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Corcept Therapeutics Faces Securities Lawsuit Over Relacorilant Clinical Trial Claims

Rosen Law Firm seeks lead plaintiffs in securities class action against Corcept Therapeutics, alleging misrepresentation of FDA communications and clinical trial data for relacorilant drug.
CORTsecurities class actionrelacorilant